Compare Lufax Holding Ltd (LU) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Lufax Holding Ltd trades at $0.99 (market cap $982.89M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 59.8× Lufax Holding Ltd's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| LU | TAK | |
|---|---|---|
Market Cap | $982.89M | $58.74B |
Volume | 3,323,384 | 3,110,994 |
Sector | Financials | Health |
52-Week High | $3.93 | $19.05 |
52-Week Low | $0.95 | $13.23 |
Typical Hold Time | 13 Days | 1 Days |
Enterprise Value | $58.81B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lufax (LU) trades at $0.986, up 0.47% on the day, but shows significant fundamental challenges with consecutive quarterly losses and declining revenue. The company recently completed a 10:1 reverse stock split and faces bearish technical signals despite some oversold RSI readings. Analyst sentiment remains predominantly bullish with 69% buy ratings, pointing to potential value in the depressed valuation multiples.
The investment case hinges on Lufax's deep value proposition trading at 0.07x book value, but requires successful navigation of regulatory headwinds and return to profitability. Key risks include persistent net losses, Chinese regulatory uncertainty, and declining top-line performance that could pressure the stock further despite strong institutional backing from parent company Ping An.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
